TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21355087
Drug: Doxorubicin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 25 mg/m(2), vinblastine 6 mg/m(2), and gemcitabine 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days for 6 cycles
Study: 21355097
Drug: Romidepsin (depsipeptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romidepsin (depsipeptide or FK228), a histone deacetylase inhibitor
Study: 21355725
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy (Animas(®) 2020, Animas Corp.) for 16 weeks
Study: 21356058
Drug: Other gastrointestinal
Normalized name: INVESTIGATIONAL DRUGS FOR OTHER GASTROINTESTINAL DISEASES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other gastrointestinal drugs (except PPIs)
Study: 21356079
Drug: Canakinumab 2
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 2 mg/kg subcutaneously (s.c.) for patients with body weight ≤ 40 kg or 150 mg s.c. for patients with body weight > 40 kg.
Study: 21356124
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) 0.5 mg/kg normal body weight/day, injected subcutaneously for 14 days, followed by a break of one week, repeated to a maximum of nine times.
Study: 21356124
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) treatment in 12 patients who completed all nine cycles.
Study: 21356124
Drug: 15-deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-deoxyspergualin (DSG) treatment in 20 patients.
Study: 21358295
Drug: Capecitabine (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,250 mg/m² twice daily for 14 days, followed by 14 days of rest)
Study: 21358415
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of left ventricular hypertrophy by Cornell product (1 year) or UACR (1 year) at least 1 mmol/l
Study: 21359193
Drug: Iodine deficiency
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine deficiency (mean urinary iodine excretion, 49.8 µg/L)
Study: 21359953
Drug: Lapatinib 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,000 mg/day and nab-paclitaxel 260 mg/m2 every 3 weeks for four cycles
Study: 21366812
Drug: G-allele of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-allele of rs10830963
Study: 21367942
Drug: Serum potassium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum potassium concentrations <4.0 mEq/L
Study: 21367942
Drug: Serum potassium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum potassium concentrations 4.0-4.4 mEq/L
Study: 21367942
Drug: Serum potassium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum potassium concentrations 4.5-4.9 mEq/L
Study: 21371308
Drug: Extracorporeal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal plasma treatment with a granulocyte bioreactor, treated twice within 72 hours for a mean of 342 ± 64 minutes/treatment with 1.41 ± 0.43 × 10E10 granulocytes from healthy donors.
Study: 21371308
Drug: Extracorporeal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal plasma treatment with a granulocyte bioreactor
Study: 21372218
Drug: E7080 13
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7080 13 mg bid
Study: 21372302
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day simvastatin
Study: 21372302
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day simvastatin
Study: 21372302
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day simvastatin (48 hours after admission)
Study: 21372302
Drug: Early statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early statin treatment
Study: 21372302
Drug: Higher statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher statin doses
Study: 21377509
Drug: H6N1 influenza
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: H6N1 influenza virus vaccine (10^7 TCID(50), 2 doses)
Study: 21377509
Drug: H6N1 influenza
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: H6N1 influenza virus vaccine (2 doses)
Study: 21377994
Drug: Romidepsin at
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin at a dosage of 13.3 mg/m(2)/day on days 1, 8, and 15 of each 28-day cycle (phase II component)
Study: 21377994
Drug: Romidepsin at
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin at a dosage of 17.7 mg/m(2)/d (phase I component)
Study: 21377994
Drug: Romidepsin at
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin at a dosage of 13.3 mg/m(2)/d (phase I component)
Study: 21380781
Drug: Zoladex combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex combined with CEF chemotherapy
Study: 21381892
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) 300 μg weekly
Study: 21382172
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (Clopidogrel and Aspirin)
Study: 21383285
Drug: ARQ 197
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ 197 at 100 to 400 mg twice per day
Study: 21383338
Drug: Voriconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (200 mg)
Study: 21386092
Drug: 81 mg/od
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg/od
Study: 21386092
Drug: 81 mg/bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg/bid
Study: 21386092
Drug: 162 mg/bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 162 mg/bid
Study: 21386092
Drug: Aspirin dosing
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin dosing regimens
Study: 21386997
Drug: H5N1 inactivated
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 inactivated sub-virion vaccine
Study: 21389182
Drug: G/G genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/G genotype with low saturated fatty acid (SFA) concentrations (below the median)
Study: 21389182
Drug: G/G genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/G genotype with high saturated fatty acid (SFA) concentrations (above the median)
Study: 21389182
Drug: Minor A
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor A allele (G/A and A/A) with high saturated fatty acid (SFA) concentrations
Study: 21391024
Drug: Clinician ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician ratings of treatment improvement
Study: 21393329
Drug: Deferasirox monotherapy
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox monotherapy (30-40 mg/kg/day) for 18 months
Study: 21393334
Drug: Early discharge
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early discharge after chemotherapy completion with close outpatient follow up
Study: 21394036
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg alone
Study: 21394036
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg with Amlodipine 10 mg
Study: 21394036
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg with Fimasartan 120 mg
Study: 21395631
Drug: Enteric-coated cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated cysteamine (mean dose 15.2 mg/kg/day) for 24 weeks
Study: 21396809
Drug: Continuous supplemental
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous supplemental oxygen therapy
Study: 21398104
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol (MF/F) metered-dose inhaler (MDI) 100/10 μg with integrated dose counter, used twice daily for 4 weeks
Study: 21398104
Drug: MF/F MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F MDI with integrated dose counter
Study: 21398296
Drug: Panobacumab (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobacumab (1.2 mg/kg, given every 72 h)
Study: 21398392
Drug: DNA vaccine
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine encoding the protein premembrane and the E glycoproteins of the NY99 strain of WNV, administered in a 3-dose regimen.
Study: 21402043
Drug: Vaccination coverage
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination coverage for all vaccines part of the Expanded Program on Immunization (EPI)
Study: 21402043
Drug: All recommended
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All recommended vaccines received
Study: 21402043
Drug: Timely vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely vaccination for measles vaccine
Study: 21402043
Drug: Timely vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely vaccination for Bacillus Calmette-Guérin (BCG) vaccine
Study: 21402043
Drug: All vaccines
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccines received within recommended time ranges
Study: 21406109
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of standardized Ginkgo biloba two times per day for 12 weeks
Study: 21406512
Drug: Antibiotic prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescription for patients producing discoloured sputum
Study: 21406512
Drug: Antibiotic prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescription for patients producing clear/white sputum
Study: 21406512
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for patients producing yellow sputum
Study: 21406512
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for patients producing green sputum
Study: 21406512
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for patients feeling unwell
Study: 21406512
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for patients producing discoloured sputum and feeling unwell
Study: 21410411
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hepatitis B virus-associated membranous nephritis
Study: 21410954
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) provided by community health workers (CHWs) for unsupervised treatment at home
Study: 21410960
Drug: Escitalopram up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram up to 50 mg
Study: 21411559
Drug: Thyroid antibody
Normalized name: Thyroid antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid antibody positive (n=245)
Study: 21411559
Drug: Thyroid antibody
Normalized name: Thyroid antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid antibody negative (n=3348)
Study: 21414193
Drug: Zibotentan 10
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 10 mg (single oral dose)
Study: 21414495
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg at week 0, then 40 mg every other week from week 1)
Study: 21415315
Drug: Home short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home short daily hemodialysis (SDHD) 6 times/week
Study: 21415776
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² (first five patients 60 mg/m²) and pemetrexed 500 mg/m² every 21 days for three cycles with chest radiotherapy to 66 Gy, followed by docetaxel 75 mg/m² every 21 days for three cycles.
Study: 21419775
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of AS03- or MF59-adjuvanted vaccines in immunocompetent children
Study: 21419775
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of AS03- or MF59-adjuvanted vaccines in immunocompromised children
Study: 21425150
Drug: Clofarabine (CLO)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (CLO) 4 mg/m², administered as a 1-hour intravenous infusion daily for 5 days every 28 days (maximum 6 cycles)
Study: 21425247
Drug: Novartis MF59-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novartis MF59-adjuvanted H1N1v monovalent influenza vaccine
Study: 21426510
Drug: Hemodialysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis treatment with secondary hyperparathyroidism management
Study: 21426511
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC) treatment, flexible daily dosage of 750-4500 mg
Study: 21426511
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC) treatment
Study: 21429209
Drug: Tissue Doppler
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue Doppler imaging systolic longitudinal ventricular velocity of the lateral wall (S'l)
Study: 21429209
Drug: Tissue Doppler
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue Doppler imaging early diastolic longitudinal ventricular velocity of the lateral wall (E'l)
Study: 21429209
Drug: Tissue Doppler
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue Doppler imaging late diastolic longitudinal ventricular velocity of the lateral wall (A'l)
Study: 21429209
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and insulin concentrations
Study: 21433272
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/hr infusion)
Study: 21436454
Drug: CD40 agonist
Normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD40 agonist antibody combined with gemcitabine chemotherapy
Study: 21436454
Drug: CD40 agonist
Normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD40 agonist antibody
Study: 21440503
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg/week and rituximab 375 mg/m(2) per week for 4 weeks, then rituximab every other 28-day cycle for a total of 12 cycles.
Study: 21440503
Drug: Treatment-related adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related adverse events in rituximab-sensitive patients.
Study: 21440503
Drug: Treatment-related adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related adverse events in rituximab-refractory patients.
Study: 21441399
Drug: Single urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single urinary albumin excretion (UAE) measurement
Study: 21441399
Drug: Albumin excretion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin excretion rate (AER) measurement
Study: 21444917
Drug: Prephase chemotherapy
Normalized name: estrogens, conjugated (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prephase chemotherapy followed by 3 courses of chemotherapy (for 6 patients with complete resection)
Study: 21444917
Drug: Prephase chemotherapy
Normalized name: estrogens, conjugated (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prephase chemotherapy followed by 6 courses of chemotherapy (for 30 patients without complete resection)
Study: 21447719
Drug: AS1409 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS1409 at 15 μg/kg weekly
Study: 21450159
Drug: Ketamine, acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine, acute course, dosage and duration not specified
Study: 21450573
Drug: Carvedilol at
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol at maximal tolerated dose
Study: 21454794
Drug: Mitochondrial tRNA(Ile)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitochondrial tRNA(Ile) 4263A>G mutation
Study: 21454794
Drug: Mitochondrial dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitochondrial dysfunction due to 4263A>G mutation
Study: 21454813
Drug: Intravenous dantrolene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dantrolene 1.25 mg/kg
Study: 21454813
Drug: Intravenous dantrolene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dantrolene 2.5 mg/kg
Study: 21455550
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg BIW for 12 weeks followed by 50 mg OW for 12 weeks
Study: 21458098
Drug: Adiponectin to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin to homeostasis model assessment of insulin resistance (A/H ratio)
Study: 21459588
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy (BNCT) combined with fractionated X-ray irradiation and temozolomide.
Study: 21459796
Drug: GSK461364 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK461364 administered intravenously at 300 mg (schedule A)
Study: 21459796
Drug: GSK461364 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK461364 administered intravenously at 225 mg (schedule A)
Study: 21459796
Drug: GSK461364 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK461364 administered intravenously at 100 mg (schedule B)
Study: 21459796
Drug: GSK461364 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK461364 administered intravenously (both schedules)
Study: 21459796
Drug: GSK461364 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK461364 at 225 mg (schedule A)
Study: 21463526
Drug: Injectable risperidone
Normalized name: risperidone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable risperidone long-acting therapy (RLAT)
Study: 21463793
Drug: Esophageal stenting
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal stenting during neoadjuvant therapy
Study: 21464053
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use
Study: 21464053
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy for atrial fibrillation
Study: 21464053
Drug: Aldosterone antagonist
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonist use
Study: 21464155
Drug: Overall imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall imatinib treatment
Study: 21464155
Drug: Overall sunitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall sunitinib treatment
Study: 21464430
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPD) up to 80 mg/day
Study: 21465636
Drug: Oral imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral imatinib at 340 mg/m²
Study: 21467128
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no change in medication)
Study: 21468309
Drug: Single 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400 mg dose of albendazole (ALB)
Study: 21470010
Drug: XRX-001 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XRX-001 vaccine (4.8 μg antigen)
Study: 21470010
Drug: XRX-001 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XRX-001 vaccine (0.48 μg antigen)
Study: 21470010
Drug: XRX-001 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XRX-001 vaccine (both dosages)
Study: 21470045
Drug: etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: etravirine (ETR) 200 mg twice daily
Study: 21471286
Drug: Gefitinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (500 mg for 5 days before surgery and continued postoperatively until recurrence)
Study: 21471568
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of intestinal anti-TG2 antibodies
Study: 21473790
Drug: Vorinostat in
Normalized name: Product containing vorinostat in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat in combination with pelvic palliative radiotherapy